Eniluracil

N/A

Report date: 2024/09/30 20:00:32
NME

Base Information

Drug NameEniluracil
Drug Alias Name5-Ethynyluracil恩尿嘧啶eniluracilumeniluraciloeniluracil +[13] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDihydropyrimidine dehydrogenase inhibitors
TargetsDihydropyrimidine dehydrogenase
Therapy Area/IndicationsMetastatic breast cancerHead and Neck NeoplasmsStomach Neoplasms +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSingaporeTaiwan +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesProcessa Pharmaceuticals Inc
Inactive CompaniesRobert H. Lurie Comprehensive Cancer Center Of Northwestern UniversityGlaxo Wellcome IncNational Cancer Institute +[6] 
Active IndicationsStomach NeoplasmsTriple Negative Breast NeoplasmsBreast Neoplasms
Inactive IndicationsMetastatic breast cancerHead and Neck NeoplasmsRectal Neoplasms +[8] 

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG